



WHITTEMORE PETERSON
INSTITUTE FOR NEURO-IMMUNE DISEASE

August 23, 2010

**Statement on XMRV/Chronic Fatigue Syndrome
*Positive replication study confirms WPI's findings***

The Whittemore Peterson Institute(WPI) would like to congratulate the distinguished authors of the recently released replication study linking XMRV with Chronic Fatigue Syndrome, Dr. Shyh-Ching Lo of the Food and Drug Administration (FDA) and Dr. Harvey Alter of the National Institutes of Health (NIH). Their published findings in the *Proceedings of the National Academy of Sciences (PNAS)* , [confirm the central thesis of WPI's 2009 study](#) associating a new human gamma retrovirus, XMRV, with patients diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) while also providing answers for the failure of others to find such a link.

Validation by these prestigious researchers from two United States governmental agencies demonstrates the need for expanded research on human gamma retroviral infection and its association to ME/CFS and other neuro-immune diseases.

“We are hopeful that with continued collaboration between our government, the biomedical industry and institutions such as the WPI, we will continue to discover answers for the millions around the world who suffer with neuro-immune diseases,” said [Annette Whittemore](#), president and founder of the Whittemore Peterson Institute. For additional thoughts by Dr. Judy Mikovits, [please view here](#).

The WPI is committed to the research and further understanding of XMRV and its relationship to neuro-immune disease. With the recent opening of the institute's new translational research facilities located on the medical school campus of the University of Nevada, Reno, come expanded opportunities for new avenues of research and development of effective diagnostics and treatments for those affected by neuro-immune disease.

###